Storm-tossed Qiagen plots a course to higher growth
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
TCT 2019 – Abbott's aortic valve disappoints
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
TCT 2019 – Orchestra data could lead to a duet
Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.
Esmo 2019 – Foundation eyes liquid biopsy rule change
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
Medtronic bets on flexibility for its surgical robots
The long-awaited robotic surgery system is designed to open up the market.
The contrasting fortunes of Envista and Smiledirectclub
Two dental companies go public inside a week, with very different results.
Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
With new unicorn status, CMR Surgical sets profitability target
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
Nuvaira hopes to go with the flow in COPD
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.